What will happen to insulin users?

As GLP-1 sales surge, patients suddenly can't find enough of the insulins made by companies they have long relied on to do so

July 17, 2024 Check out STAT+

Sponsored By

Eddie Quinones for STAT As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them The diabetes community fears the drugmakers, which have long provided insulin, are prioritizing the development and sale of GLP-1 weight loss medications. By Elaine Chen STAT+ | Elevance tumbles as health insurer warns Medicaid members are using more care Elevance said the amount of care its Medicaid members are getting is outpacing what states are paying the insurer to cover them By Tara Bannow STAT+ | Data privacy startup raises $30 million, to ease health care providers' regulatory burden Health tech startup Freshpaint has raised $30 million to sell its health data privacy platform to providers, pharmacies, insurers. By Mohana Ravindranath Adobe STAT+ | A Senate bill was touted as a cure for 'patent thickets.' Some say the drug industry watered it down Designed to cut drug prices through greater competition, the Affordable Prescriptions for Patients Act is "a shadow of its former self," one expert said. By Ed Silverman and Rachel Cohrs Zhang STAT+ | A second Roche obesity drug shows promise in early studies The drug, called CT-996, is one of several experimental medicines Roche is advancing as it tries to enter the booming obesity medicine field. By Andrew Joseph STAT+ | Why clinical trials for digital therapeutics are getting more rigorous Increasing rigor, and better evidence, can help digital therapeutics companies convince critics that their novel treatments are valuable. By Mario Aguilar Molly Ferguson/STAT STAT+ | With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer's disease world Remi Barbier, Cassava's CEO, has resigned and is also leaving the board. Lindsay Burns, Cassava's senior vice president of neuroscience, is gone, too. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser